We are now well into what is often called the “psychedelic renaissance,” and the field has made genuine progress alongside all the early excitement. Many groups new to the realities of FDA oversight and the complexity of clinical development have learned that translating classic psychedelics into approved treatments is far more challenging than initially imagined. Still, this early work has significantly expanded our understanding of how to target key regions of the brain and reframe mental healthcare.
